Dr. Reddy's Laboratories reported a significant decline in its fourth-quarter results, with consolidated net profit falling 86% year-over-year [1].
The results highlight a period of earnings pressure and margin compression for the pharmaceutical company. As the firm navigates a dip in revenue, its ability to hit future margin targets will be critical for investor confidence.
Consolidated net profit for the quarter ending March 2026 reached Rs 221 crore [1]. This drop coincides with a 12% decline in revenue compared to the previous year [1]. Despite the subdued financial performance, the company announced a dividend of Rs eight per share [1].
To counter these losses, Dr. Reddy's is focusing on its U.S. business. The company is targeting double-digit growth in the U.S. market, excluding the impact of Revlimid and Semaglutide [2].
Regarding operational efficiency, the company achieved an EBITDA margin of 19.5% when excluding Lenalidomide and Semaglutide [3]. Looking forward, the company said it aims for an EBITDA margin in the range of 20% to 25% for fiscal year 2027 [3].
Management said that the current strategy involves balancing growth in the U.S. with tighter cost controls to stabilize the bottom line, a move intended to reverse the current downward trend in profitability.
“Consolidated net profit for Q4 fell 86% year-over-year to Rs 221 crore.”
The sharp decline in net profit suggests that Dr. Reddy's is facing significant headwinds, likely due to a combination of lower pricing or volume in key markets. By setting a specific EBITDA margin target for FY27 and focusing on non-blockbuster growth in the U.S., the company is attempting to signal a shift toward sustainable, organic growth rather than relying on a few high-revenue products.
